Mylan to Face EpiPen Classification, Rebate Class Fraud Claims

Securities fraud claims by Mylan NV investors that it misclassified EpiPens as generic and paid pharmacy benefit managers anticompetitive rebates may proceed as a class action, a federal district court in New York said Monday.